Medicine and Health

How to use COVID-19 antiviral drugs in patients with chronic kidney disease

A. Kale, V. Shelke, et al.

This comprehensive review explores the pharmacokinetics and safety of COVID-19 antiviral drugs in chronic kidney disease patients. Conducted by leading researchers including Ajinath Kale and Hans-Joachim Anders, it highlights vital dosage recommendations and safety profiles for various antiviral agents. Dive in to discover which treatments can make a difference for those with CKD facing COVID-19.

00:00

Playback language: English

Index

Abstract

This review examines the pharmacokinetics, pharmacology, rationale, limitations, and adverse effects of COVID-19 antiviral drugs in patients with chronic kidney disease (CKD). It analyzes data from various databases and clinical trials, focusing on drugs like remdesivir, molnupiravir, famciclovir, ribavirin, favipiravir, atazanavir, darunavir, nirmatrelvir/ritonavir, lopinavir/ritonavir, oseltamivir, azvudine, and dolutegravir/rilpivirine, as well as monoclonal antibodies. The review provides dosage recommendations and precautions based on CKD stage and drug characteristics, highlighting which antivirals are safe and which should be avoided in CKD patients. The authors conclude with a ranked list of antivirals based on their safety profile in CKD patients with COVID-19, emphasizing the need for further research to establish definitive guidelines.

Publisher

Frontiers in Pharmacology

Published On

Sep 26, 2023

Authors

Ajinath Kale, Vishwadeep Shelke, Neha Dagar, Hans-Joachim Anders, Anil Bhanudas Gaikwad

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

J. F. E. Mann, P. Rossing, et al.

Medicine and Health

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease

N. Snelder, R. Heinig, et al.

Medicine and Health

Inflammation as a diagnostic criterion in the GLIM definition of malnutrition—what CRP-threshold relates to reduced food intake in older patients with acute disease?

M. Pourhassan, T. Cederholm, et al.

Medicine and Health

Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial

A. Podadera-herreros, A. P. A. Larriva, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny